ADVANCED PHARMACOLOGY FOR
w w ww
PRESCRIBERS 1ST EDITION BY LUO K
w w w w w
AYINGO TEST BANK | 2024 UPDATE
w w w w w
, Table of Contents
w w
Chapterw 1:wAnwIntroductionwtowEvidence-BasedwClinicalw PracticewGuidelines ............................................ 3
Chapterw2:wPharmacokineticsw/Chapter3:wPharmacodynamics.................................................................... 13
Chapter4:wPharmacogeneticswandwPharmacogenomics ............................................................................... 25
Chapterw5:wPharmacologywAcrosswthewLifewSpan ....................................................................................... 30
Chapterw6:wDrug-TherapywPrescribingwinwSpecialwPopulations................................................................... 36
Chapterw7:wDrugwDevelopmentwandwApproval ............................................................................................ 45
Chapterw8-Chapterw10:wFoundationswofwPrescriptionwWritingwChapterw9:wResponsibleControlled-
SubstancewPrescribingwChapterw10:wAntibioticwStewardship ....................................................................... 51
Chapterw11:wAppliedwCalculationswforwPrescribing..................................................................................... 58
Chapterw12-:wPromotingwAdherencewWithwPharmacotherapywII:wSystem-SpecificwandwPatient-
FocusedwPrescribingwChapterw13:wPharmacotherapywforwEar,wNose,wMouth,wandThroatwConditionsw/Chapte
rw14:wPharmacotherapywforwEyewConditions ................................................................................................ 67
Chapterw15:wPharmacotherapywforwSkinwConditions ................................................................................... 74
Chapterw16:wPharmacotherapywforw NeurologicwConditions ........................................................................ 81
Chapterw 17:wPharmacotherapywforwCardiovascularw Conditions .................................................................. 94
Chapterw 18:wPharmacotherapywforwRespiratorywConditions...................................................................... 106
Chapterw19:wPharmacotherapywforwGastrointestinalwConditionswandwConditionswRequiringNutritionalwSupp
ort .............................................................................................................................................................. 117
Chapterw 20:wPharmacotherapywforwGenitourinarywConditions .................................................................. 128
Chapterw21:wPharmacotherapywforwRenal,wAcid–Base,wFluid,wandwElectrolytewDisorders ....................... 133
Chapterw22:wPharmacotherapywforwMusculoskeletalwandwRheumatologicwConditions ............................. 146
Chapterw23:wTherapeuticw Applicationsw ofwImmunologywandwVaccines ................................................... 158
Chapterw 24:wPharmacotherapywforw EndocrinewDisorders .......................................................................... 163
Chapterw25:wPharmacotherapywforwHematologicwDisorders ...................................................................... 174
Chapterw26:wHematology/OncologywandwSupportivewCarewforwthewNononcologist .................................. 190
Chapterw 27:wPharmacotherapywRelatedwtowWomen’swHealthwConditions................................................. 196
Chapterw28:wPharmacotherapywRelatedwtowMen’swHealthwConditions ...................................................... 211
Chapterw 29:wPharmacotherapywRelatedwtowTransgenderw Care .................................................................. 217
Chapterw30:wAntimicrobialwPharmacotherapy ........................................................................................... 224
Chapterw 31:wAntiretroviralwPharmacotherapy............................................................................................ 235
Chapterw32:wPsychopharmacologywandwIntegrativewHealth:wCombinedwTreatmentwofPsychiatricwandwNeuro
cognitivew Conditions.................................................................................................................................. 247
Chapterw 33:wPharmacotherapywforwPainwManagement .............................................................................. 257
Chapterw34:wSubstancewUsewDisorderw III:wHealthwPromotionwandwMaintenance ...................................... 267
Chapterw35:wOver-the-CounterwMedications ............................................................................................. 283
Chapterw36:wPharmacotherapywforwObesity ............................................................................................... 291
,Chapterw1:wAnwIntroductionwtowEvidence-BasedwClinicalwPracticewGuidelines
MULTIPLEwCHOICE
• Whatwiswthewprimarywpurposewofwthewnursingw assessment?
A. Identifyingwunderlyingw pathologicw conditions
B. Assistingw thewphysicianwinwidentifyingwmedicalw conditions
C. Determiningwthewpatientswmentalwstatus
D. Exploringwpatientwresponseswtow healthwproblems
ANS:wD
Awnursingwassessmentwiswdonewtowidentifywthewpatientswresponsewtowhealthwp
roblems.wDuringwthewnursingwassessmentwphase,wawcomprehensivewinformat
ionwbasewiswdevelopedwthroughwawphysicalwexamination,wnursingwhistory,wm
edicationwhistory,wandwprofessionalwobservation.wIdentifyingwunderlyingwpa
thologicwconditionswandwassistingwthewphysicianwinwidentifyingwmedicalwcon
ditionswiswnotwpartwofwthewnursingwprocess.wDeterminingwthewpatientsw menta
lwstatusw iswonewpartw ofwthew nursingw assessment,w butw itw isw notwthewprimaryw
purpose.
DIF:wCognitivewLevel:wComprehension
wREF: wdmw36wOBJ:w1w|w3wTOP:wNursin
gwProcesswStep:wAssessment
MSC:wNCLEXw ClientwNeedsw Category:wHealthwPromotionwandwMaintenance
• WhatwiswthewbasiswofwthewNANDAwIw taxonomy?
A. Functionalwhealthwpatterns
B. Humanwresponsewpatterns
C. Basicwhumanwneeds
D. Pathophysiologicw needs
ANS:wB
Thew NANDAw Iw taxonomyw identifiesw humanw responsew patterns.wFunctio
nalwcomponentswofwhealthwpatternswarewlimitedwtowactivity,wfluidwvolume,w
nutrition,wselfwcare,wandwsensorywperception.wBasicwhumanwneedswcompris
ewlesswthanwmerelywhealthwpatterns.w Pathophysiologicwneedsw arewnotwpartw
ofwthewscopewofwNANDAwI.
, DIF:wCognitivewLevel:wKnowledgewRE
F:wpp.w37-38wOBJ:w5wTOP:
NursingwProcesswStep:wDiagnosis
MSC:wNCLEXwClientwNeedswCategory:wPhysiologicalw Integrity
• Whichwtaskwiswincludedwinwthewassessmentwstepwofwthewnursingw process?
A. Establishingw patientw goals/outcomes
B. Implementingwthew nursingwcarewplanw (NCP)
C. Measuringw goal/outcomew achievement
D. Collectingwandw communicatingw data
ANS:wD
Datawarewcollectedwandwcommunicatedwinwthewassessmentwphasewofwthewnurs
ingwprocess.wEstablishingwgoalswiswthewfunctionwofwplanning.
ImplementingwthewNCPwiswthewfunctionwofwimplementation.wMeasuringwout
comewachievementwiswthewfunctionwofwevaluation.
DIF:wCognitivewLevel:wComprehension
wREF: wdmw36wOBJ:w2w|w3wTOP:wNursin
gwProcesswStep:wAssessment
MSC:wNCLEXw ClientwNeedsw Category:wHealthwPromotionwandwMaintenance
• Whichwstatementwregardingw nursingwdiagnosesw isw accurate?
a. Nursingwdiagnoseswremainwthewsamew forwaswlongwaswthewdiseasewisw present.
b. Nursingwdiagnosesw arewwrittenwtowidentifywdiseasewstates.
c. Nursingwdiagnoseswdescribewpatientwproblemswthatwnursesw treat.
d. Nursingwdiagnosesw identifywcauseswrelatedwtowillness.
ANS:wC
Diagnosticwstatementswidentifywproblemswawnursewiswindependentlywablewto
wtreatwwithinwthewscopewofwprofessionalwpractice.wNursingwdiagnoseswvaryw
withwthewchangingwconditionwofwthewpatient.wThewresponsewpatternswarewuni
quewtowthewpatientwandwarewnotwdiseasewspecific.wNursingwdiagnoseswdescri
bewthewpatientswhumanwresponsewpattern.
DIF:wCognitivew Level:w Comprehension
w w ww
PRESCRIBERS 1ST EDITION BY LUO K
w w w w w
AYINGO TEST BANK | 2024 UPDATE
w w w w w
, Table of Contents
w w
Chapterw 1:wAnwIntroductionwtowEvidence-BasedwClinicalw PracticewGuidelines ............................................ 3
Chapterw2:wPharmacokineticsw/Chapter3:wPharmacodynamics.................................................................... 13
Chapter4:wPharmacogeneticswandwPharmacogenomics ............................................................................... 25
Chapterw5:wPharmacologywAcrosswthewLifewSpan ....................................................................................... 30
Chapterw6:wDrug-TherapywPrescribingwinwSpecialwPopulations................................................................... 36
Chapterw7:wDrugwDevelopmentwandwApproval ............................................................................................ 45
Chapterw8-Chapterw10:wFoundationswofwPrescriptionwWritingwChapterw9:wResponsibleControlled-
SubstancewPrescribingwChapterw10:wAntibioticwStewardship ....................................................................... 51
Chapterw11:wAppliedwCalculationswforwPrescribing..................................................................................... 58
Chapterw12-:wPromotingwAdherencewWithwPharmacotherapywII:wSystem-SpecificwandwPatient-
FocusedwPrescribingwChapterw13:wPharmacotherapywforwEar,wNose,wMouth,wandThroatwConditionsw/Chapte
rw14:wPharmacotherapywforwEyewConditions ................................................................................................ 67
Chapterw15:wPharmacotherapywforwSkinwConditions ................................................................................... 74
Chapterw16:wPharmacotherapywforw NeurologicwConditions ........................................................................ 81
Chapterw 17:wPharmacotherapywforwCardiovascularw Conditions .................................................................. 94
Chapterw 18:wPharmacotherapywforwRespiratorywConditions...................................................................... 106
Chapterw19:wPharmacotherapywforwGastrointestinalwConditionswandwConditionswRequiringNutritionalwSupp
ort .............................................................................................................................................................. 117
Chapterw 20:wPharmacotherapywforwGenitourinarywConditions .................................................................. 128
Chapterw21:wPharmacotherapywforwRenal,wAcid–Base,wFluid,wandwElectrolytewDisorders ....................... 133
Chapterw22:wPharmacotherapywforwMusculoskeletalwandwRheumatologicwConditions ............................. 146
Chapterw23:wTherapeuticw Applicationsw ofwImmunologywandwVaccines ................................................... 158
Chapterw 24:wPharmacotherapywforw EndocrinewDisorders .......................................................................... 163
Chapterw25:wPharmacotherapywforwHematologicwDisorders ...................................................................... 174
Chapterw26:wHematology/OncologywandwSupportivewCarewforwthewNononcologist .................................. 190
Chapterw 27:wPharmacotherapywRelatedwtowWomen’swHealthwConditions................................................. 196
Chapterw28:wPharmacotherapywRelatedwtowMen’swHealthwConditions ...................................................... 211
Chapterw 29:wPharmacotherapywRelatedwtowTransgenderw Care .................................................................. 217
Chapterw30:wAntimicrobialwPharmacotherapy ........................................................................................... 224
Chapterw 31:wAntiretroviralwPharmacotherapy............................................................................................ 235
Chapterw32:wPsychopharmacologywandwIntegrativewHealth:wCombinedwTreatmentwofPsychiatricwandwNeuro
cognitivew Conditions.................................................................................................................................. 247
Chapterw 33:wPharmacotherapywforwPainwManagement .............................................................................. 257
Chapterw34:wSubstancewUsewDisorderw III:wHealthwPromotionwandwMaintenance ...................................... 267
Chapterw35:wOver-the-CounterwMedications ............................................................................................. 283
Chapterw36:wPharmacotherapywforwObesity ............................................................................................... 291
,Chapterw1:wAnwIntroductionwtowEvidence-BasedwClinicalwPracticewGuidelines
MULTIPLEwCHOICE
• Whatwiswthewprimarywpurposewofwthewnursingw assessment?
A. Identifyingwunderlyingw pathologicw conditions
B. Assistingw thewphysicianwinwidentifyingwmedicalw conditions
C. Determiningwthewpatientswmentalwstatus
D. Exploringwpatientwresponseswtow healthwproblems
ANS:wD
Awnursingwassessmentwiswdonewtowidentifywthewpatientswresponsewtowhealthwp
roblems.wDuringwthewnursingwassessmentwphase,wawcomprehensivewinformat
ionwbasewiswdevelopedwthroughwawphysicalwexamination,wnursingwhistory,wm
edicationwhistory,wandwprofessionalwobservation.wIdentifyingwunderlyingwpa
thologicwconditionswandwassistingwthewphysicianwinwidentifyingwmedicalwcon
ditionswiswnotwpartwofwthewnursingwprocess.wDeterminingwthewpatientsw menta
lwstatusw iswonewpartw ofwthew nursingw assessment,w butw itw isw notwthewprimaryw
purpose.
DIF:wCognitivewLevel:wComprehension
wREF: wdmw36wOBJ:w1w|w3wTOP:wNursin
gwProcesswStep:wAssessment
MSC:wNCLEXw ClientwNeedsw Category:wHealthwPromotionwandwMaintenance
• WhatwiswthewbasiswofwthewNANDAwIw taxonomy?
A. Functionalwhealthwpatterns
B. Humanwresponsewpatterns
C. Basicwhumanwneeds
D. Pathophysiologicw needs
ANS:wB
Thew NANDAw Iw taxonomyw identifiesw humanw responsew patterns.wFunctio
nalwcomponentswofwhealthwpatternswarewlimitedwtowactivity,wfluidwvolume,w
nutrition,wselfwcare,wandwsensorywperception.wBasicwhumanwneedswcompris
ewlesswthanwmerelywhealthwpatterns.w Pathophysiologicwneedsw arewnotwpartw
ofwthewscopewofwNANDAwI.
, DIF:wCognitivewLevel:wKnowledgewRE
F:wpp.w37-38wOBJ:w5wTOP:
NursingwProcesswStep:wDiagnosis
MSC:wNCLEXwClientwNeedswCategory:wPhysiologicalw Integrity
• Whichwtaskwiswincludedwinwthewassessmentwstepwofwthewnursingw process?
A. Establishingw patientw goals/outcomes
B. Implementingwthew nursingwcarewplanw (NCP)
C. Measuringw goal/outcomew achievement
D. Collectingwandw communicatingw data
ANS:wD
Datawarewcollectedwandwcommunicatedwinwthewassessmentwphasewofwthewnurs
ingwprocess.wEstablishingwgoalswiswthewfunctionwofwplanning.
ImplementingwthewNCPwiswthewfunctionwofwimplementation.wMeasuringwout
comewachievementwiswthewfunctionwofwevaluation.
DIF:wCognitivewLevel:wComprehension
wREF: wdmw36wOBJ:w2w|w3wTOP:wNursin
gwProcesswStep:wAssessment
MSC:wNCLEXw ClientwNeedsw Category:wHealthwPromotionwandwMaintenance
• Whichwstatementwregardingw nursingwdiagnosesw isw accurate?
a. Nursingwdiagnoseswremainwthewsamew forwaswlongwaswthewdiseasewisw present.
b. Nursingwdiagnosesw arewwrittenwtowidentifywdiseasewstates.
c. Nursingwdiagnoseswdescribewpatientwproblemswthatwnursesw treat.
d. Nursingwdiagnosesw identifywcauseswrelatedwtowillness.
ANS:wC
Diagnosticwstatementswidentifywproblemswawnursewiswindependentlywablewto
wtreatwwithinwthewscopewofwprofessionalwpractice.wNursingwdiagnoseswvaryw
withwthewchangingwconditionwofwthewpatient.wThewresponsewpatternswarewuni
quewtowthewpatientwandwarewnotwdiseasewspecific.wNursingwdiagnoseswdescri
bewthewpatientswhumanwresponsewpattern.
DIF:wCognitivew Level:w Comprehension
